Introduction
============

Lifestyle and genetic factors contribute to the development of type 2 diabetes (T2D). Excessive calorie intake in combination with physical inactivity will lead to decreased body glucose disposal and insulin sensitivity resulting in impaired fasting glucose and/or impaired glucose tolerance. Around 5--10% of people with abnormal blood glucose concentrations become diabetic every year, from which 70% will go on to develop T2D.^[@bib1]^ In the United States an estimated 18.8 million people had diagnosed diabetes mellitus, whereas another 7.0 million had undiagnosed diabetes mellitus in 2010.^[@bib2]^ In Finland, 280 000 T2D diagnoses were registered in 2009 with an annual increase of 5--7% (<http://www.diabetes.fi/en/finnish_diabetes_association/diabetes_in_finland>).

Health-related risks of T2D have been investigated in several clinical trials and prospective studies.^[@bib3],\ [@bib4],\ [@bib5]^ Lifestyle changes such as increased physical exercise and weight reductions were shown to reduce the risk of T2D by ∼58%.^[@bib6],\ [@bib7]^

Recent recommendations for T2D prevention include a minimum of 150 min per week of moderate-to-vigorous PA.^[@bib8],\ [@bib9]^ Taking into account the intensity of the moderate PA (\>3 metabolic equivalents, METs) the recommendations present a relative intensity \>46% of the maximal oxygen uptake in healthy adults.^[@bib10]^ This recommendation^[@bib9]^ states also that people unable to meet these minimums can still benefit from some activity, but the intensity levels producing health benefits are not known.

Walking is the most common and most acceptable form of PA in people with T2D^[@bib10]^ and a walking speed of 4.8 km h^−1^ (3 miles h^−1^) represents moderate PA.^[@bib11]^ In the pioneering studies^[@bib6],\ [@bib7]^ regarding the effects of lifestyle changes in the prevention of T2D, the above guidelines for PA (moderate exercise 150 min weekly) were followed. Significant clinical results were observed, yet the exact amounts and intensities of PA that the participants performed in the studies^[@bib6],\ [@bib7]^ were unknown.^[@bib12]^ Thus, no threshold intensity of exercise needed to reduce metabolic risks could be attained. Furthermore, PA measurements by motion sensors have demonstrated that only very few adults meet the PA guidelines. Johnson and colleagues^[@bib13]^ used pedometers for 3 days in T2D subjects demonstrating a habitual average walking speed of 3.3 km h^−1^, which is clearly below the recommended guidelines. In other studies, the ambulatory activity was recently studied using motion sensors in a large and healthy adult USA population (NHANES). Surprisingly, less than 5% of the subjects performed PA at a moderate-intensity level.^[@bib14],\ [@bib15]^ Therefore accurate and precise measures of PA are required to elucidate lifestyle modifications decreasing T2D risks.^[@bib12]^

An alternative PA recommendation suggests to aim at 10 000 steps per day^[@bib16]^ but concerns have been expressed as health benefits may not be achieved owing to the low-intensity level of walking.^[@bib13]^ In subjects with impaired glucose tolerance, 6000--9000 steps per day of moderately intense walking resulted in decreased fasting and 2-h glucose concentrations during the 3--12-month intervention period.^[@bib17]^ Similar increases in daily step counts were observed in T2D subjects during a 16-week intervention, but no changes in fasting or 2-h glucose were apparent.^[@bib18]^ Unfortunately, walking intensity was not recorded, leading investigators to conclude that PA intensity was insufficient.^[@bib13]^ A recent cross-sectional study showed that the percentage of normal body mass index subjects having PA volume of over 10 000 steps per day was higher than that of overweight/obese subjects.^[@bib19]^

The growing prevalence of T2D and lack of objectively measured amounts and intensities of PA to improve the glycemic status in high-risk subjects have led us to perform this randomized controlled trial. Our primary aim was to investigate the effects of a 3-month structured aerobic walking exercise on fasting and 2-h glucose and insulin concentrations and lipid homeostasis in sedentary overweight subjects with impaired fasting glucose and/or impaired glucose tolerance. To achieve our aims, we recorded body weight/composition changes and nutrient intakes and measured total (habitual and structured) PA. We hypothesized that at certain PA levels of daily steps and accelerations, glucose and lipid metabolism and insulin sensitivity will improve.

Methods
=======

Trial design
------------

This trial was a parallel study with age and gender stratification in allocation ratio 1:1, performed in three centers in the city of Oulu, Finland.

Participants
------------

For this randomized controlled trial (acronym: PreDiabEx) between November 2009 and January 2010 Caucasian subjects from the outpatient diabetic clinics in the Oulu Deaconess Hospital and the City of Oulu were evaluated with the FINDRISC questionnaire for T2D (<http://www.idf.org/webdata/docs/FINDRISC_English.pdf>^[@bib20]^). Those subjects receiving scores \>15 were selected for the study. A total of 113 subjects with a median FINDRISC score of 20 (range 15--26) were further evaluated by an oral glucose tolerance test. We used the WHO criteria for impaired fasting glucose (⩾5.6 and \<7.0 and 2-h glucose \<7.8 mmol l^−1^) or impaired glucose tolerance (fasting glucose \<7.8 and 2-h glucose ⩾7.8 and \<11.1 mmol l^−1^). Seventy-eight subjects fulfilled the criteria and were willing to participate in the 3-month study ([Figure 1](#fig1){ref-type="fig"}). They were randomized based on age and gender using a parallel block design to distinguish intervention and control groups with the allocation ratio of 1:1. We used computerized random number generation. The estimated sample size to detect a 1.2-mmol l^−1^ (s.d.=2.5) change between intervention and control groups in 2-h glucose and 40-mU l^−1^ (s.d.=80) change in 2-h insulin with a significance level of 5% and a power of 80% was 65 and 62, respectively. Exclusion criteria were any functional limitation or chronic disease that might have limited the training and testing of the cardiovascular and respiratory systems, any medication for diabetes or current vigorous PA for more than 75 min per week as revealed by a questionnaire or physician\'s examination. The study protocol was approved by the institutional ethics committee (Northern Ostrobothnia Hospital District). All subjects gave their informed written consent. The Municipal Board of the Northern Ostrobothnia Hospital District approved the trial under the registration number 113/2009. The trial was also registered under NCT01649219 (clinicaltrial.gov). The CONSORT checklist is available as [Supplementary Information](#sup1){ref-type="supplementary-material"} (Checklist S1).

Questionnaires and measurements
-------------------------------

Clinical examinations and measurements were performed before (baseline) and at the end of a 3-month intervention. Height, weight, hip and waist circumference, electrocardiogram and blood pressure were measured and body mass index was calculated. Body composition was measured by bioelectrical impedance analysis InBody 720 (Mega Electronics, Kuopio, Finland). For visceral fat area a highly significant correlation (R=0.905) between the bioimpedance and computed tomography methods has been previously documented.^[@bib21]^

A self-administered questionnaire^[@bib22]^ with questions on PA health condition, medications, smoking, alcohol use, profession and education was distributed to all subjects before the experiments. The questionnaire has previously been validated.^[@bib23]^ For the leisure-time PA, the daily durations of PA (⩾15 min, 15--30 min or ⩾30 min) and intensities (light: slow walking; moderate: brisk walking; vigorous: running and jogging) were asked and expressed as metabolic units (MET). Light PA was 0--3, moderate 3--6 and vigorous 6--9 METs. They were combined to MET h per week using means of the physical activities of 1.5, 4.5 and 7.5 METs, respectively. A 3-day dietary questionnaire with a colored dietary atlas of usual food and drink items^[@bib24]^ was distributed to the subjects before and after the intervention. A professional dietician counseled the subjects in filling up the questionnaire. An oral glucose tolerance test was performed in the morning after an overnight fast according to WHO instructions. Fasting and 2-h plasma glucose and insulin were measured by direct methods using an Advia 1800, Siemens (Tarrytown, NY, USA). Plasma total cholesterol, high-density lipoprotein (HDL-) and low-density lipoprotein (LDL) cholesterols and triglycerides were determined by direct methods using an Advia Centaur XP, Siemens. Homeostasis model assessment-estimated insulin resistance (HOMA-IR) was calculated from fasting serum levels of glucose and insulin as follows: HOMA-IR=insulin (μIU ml^−1^) × glucose (mmol l^−1^)/22.5.

Indirect submaximal oxygen uptake tests were performed using a cycle ergometer (Schiller ergometer 911S, Baar, Switzerland and Monark ergometer 828E, Varberg, Sweden).^[@bib25]^ Heart rate was recorded using a heart rate monitor (M61, Polar Electro, Kempele, Finland) at three resistance levels (30, 60 and 90 W) each lasting for 4 min. Resistances of 30, 50 and 70 W were used, if the subject had uncomfortable feelings or exhaustion at the 30-W level. Blood pressure and blood lactic acid (Lactate Pro, Argray Inc., Kojo, Japan) were measured at each resistance level.

Intervention
------------

We wanted to follow the ACSM 2011 recommendation^[@bib9]^ for the exercise for healthy adults (150 min per week of moderate PA). The training sessions of the intervention group were carried out in an indoor sports hall three times a week over a period of 3 months and were supervised by an exercise instructor and a physician. Each session lasted for 60 min and included a 5-min warm-up and stretching, 20-min walk at a speed of ∼3--4 km h^−1^ on plane area (depending on the participant\'s physical condition). Most subjects were not able to walk at a speed of 5 km h^−1^ required for moderate PA. Walking was followed by a 5-min stretching and balance training, a 20-min walk and a 10-min stretching and balance exercise. After 1.5 months the 5-min stretching and balance training between the two 20-min walks were eliminated, and walking time was increased to 45 min. During the 3-month intervention period, 32 sessions were held with a median adherence of 22 times (67% range 11--31 times). Before the intervention, all subjects together with the investigators, a dietician and nurses attended two sessions of 60 min in which the exercise intervention program, the identification of abnormal glucose tolerance and the significance of regular PA and weight reduction to prevent the development of T2D as the best standard care were addressed. The intervention participants met the athletic instructor three times a week during the structured exercises. The control participants group met research assistants once a week for downloading the data from the accelerometers.

Objective measurement of PA
---------------------------

All subjects carried an accelerometer (Newtest Exercise Monitor, Newtest, Oulu, Finland), except during bathing and other aquatic activities, during the waking hours, every day for 3 months to avoid confounding effects by weekends, holidays and weather. The device was worn on a belt close to the right iliac crest or clipped to trousers. Before the trial, the subjects familiarized themselves with the use of the accelerometer, but no pre-intervention data were collected.

The device recorded the number of vertical accelerations at a sampling rate of 400 s^−1^ and classified them according to peak acceleration to 33 acceleration levels from 0.3--9.9 g (g=gravity acceleration 9.81 m^−2^; standing is 0 g). The reproducibility of the accelerometer to register acceleration peaks and their correlations with force plate accelerations have been described earlier.^[@bib26],\ [@bib27]^ The variation in the weighted average of accelerations in walking/running speeds of 3, 6 and 6 km h^−1^ accounted for 92% of the variance in the energy expenditure ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}).

The device was sealed in order not to give any feedback to the user. Average daily distribution of steps was analyzed with a custom-made computer software (Matlab, Mathworks Inc., Natick, MA, USA), and a valid day consisted of more than 1000 steps. The daily wear-time was checked 1--2 times weekly during downloading the data. The median for the whole-day wear-time was 78 days (range 26--93 in the intervention and 24--90 in the control group). The mean total number of steps per day and number of steps at different acceleration classes (0.3--0.5, 0.5--0.7, 0.7--0.9, 0.9--1.1, 1.1--3 and ⩾3 g) were used to describe PA during the whole 12-week trial. We used steps with intensities between 0.3--9.9 g as markers of steps during walking and running. Sitting or very slow walking (below 1 km h^−1^ or a step ∼every 3--4 s) induces accelerations below 0.3 g, which were not registered. Walking at a speed of 3 km h^−1^ induces steps with intensities of 0.7--0.9 g and at 5 km h^−1^ intensities of 0.8--1.2 g.^[@bib28]^ We have previously observed that beneficial health effects in maximal oxygen uptake and cholesterol levels in healthy women appear only when the step intensities exceed 1.1 g.^[@bib29]^

Outcome
-------

The primary outcome measures were fasting and 2-h glucose and insulin. The secondary outcomes were maximal oxygen uptake, daily steps, lipids and body weight and fat distributions.

Statistical analyses
--------------------

The data were analyzed using the SPSS statistical package (PASW statistics 18 for Windows, SPSS Inc., Chicago, IL, USA). Unpaired two-tailed *t*-test and *χ*^2^-test were used to compare participant characteristics at baseline. The efficacy of the intervention on primary and secondary end points was assessed using a unpaired *t*-test based on the original values or on logarithmic transformations, or a nonparametric test (Mann--Whitney, details in Tables and Figures). Repeated measures analysis of variance was used to determine the effect of the intervention on glucose, insulin and lipid concentrations, body constituents and macronutrients and controlled for potential confounding variables like baseline (model 1), sex, age (model 2, including baseline) and body weight changes (model 3 including baseline, sex and age). Mixed models for repeated measurements were used to analyze weekly impact data. Group randomization was used as a covariant in the analysis of insulin, LDL cholesterol and visceral fat data. We also evaluated the effects of daily total PA on our outcome variables by combining them together from both groups, dividing to quartiles based on the average number of steps per day and comparing the variables between the least and most active quartiles using Dunnett\'s test.

Results
=======

The characteristics of the study groups were similar at baseline in anthropometric, fitness and educational data, smoking, alcohol consumption and medication ([Table 1](#tbl1){ref-type="table"}). Systolic blood pressure was higher in the control than in the intervention group.

The changes in the outcome parameters at baseline and at 3 months and differences between the groups are shown in [Table 2](#tbl2){ref-type="table"}. In the intervention group fasting and 2-h glucose decreased significantly, but in the control group no significant changes were found. The fasting and 2-h glucose between the intervention and control groups were not significant. In the intervention group fasting and 2-h insulin decreased significantly, whereas in the control group no significant changes were observed. The differences in the changes of the unadjusted fasting and 2-h insulin concentrations between the intervention and control groups were 3.4 mU l^−1^ (*P*=0.047) and 26.6 mU l^−1^ (*P*=0.003), respectively. After the adjustment for baseline, age, gender and weight change, the *P*-values remained at the same level. HOMA-IR decreased by 1.1 (*P*=0.003) in the intervention group, but no significant change was detected in the control group. The difference of unadjusted HOMA-IR values between the groups was significant (*P*=0.050), whereas the adjustment changed the *P*-value slightly (*P*=0.036).

Total plasma cholesterol and triglycerides decreased significantly during the 3 months in the intervention group, but no changes were seen in the control group. The difference between the changes of LDL cholesterol in the intervention and control group was significant (*P*=0.014) and the adjustment (baseline, age, gender and body weight change) changed the *P*-value (*P*=0.008). The difference between changes of total cholesterol was not significant, but became significant after the adjustment had been made (*P*=0.041).

During the 3 months intervention, body weight and body mass index decreased significantly in both groups and waist circumference (*P*=0.005) in the control group, but no significant differences in the decreases between the groups were observed. Systolic and diastolic blood pressures decreased significantly in both groups, but the difference between the intervention and control groups was not significant.

Visceral fat area significantly decreased during the 3 months in the intervention (*P*=0.013), but not in the control group. The differences of unadjusted values between the groups were not significant (*P*=0.073), but became significant (*P*=0.030) after the adjustment of baseline, age, gender and body weight change. The total energy intake, based on protein, carbohydrate and fat intakes, did not show any significant changes during the 3 months in both groups and the differences between the groups were not significant.

Between 0 and 3 months, there were significant increases in maximal oxygen uptake values in both intervention and control groups ([Table 2](#tbl2){ref-type="table"}). However, these increases were not different between the groups (*P*⩾0.05).

Accelerometer data were recorded through the whole 3-month study. Mean numbers of the daily steps showed large variations between the subjects ([Figure 2](#fig2){ref-type="fig"}). In both groups (medians of weekly steps; [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}) there were no significant step differences between the intervention vs control group in any week during the entire study time nor was there a difference in between the weeks. There was no group × time interaction (*P*=0.214). The total daily number of steps (average daily step count summarized across all time points; acceleration classes 0.3--⩾1.1) was higher in the intervention than in the control group, median 5576 (range 1196--15 687 vs 4004 (range 2119--23 088) steps. Over 80% of the daily steps clustered at the acceleration classes 0.3--0.7 g and were 5870±3277 (mean±s.d.) in the intervention and 4434±3460 in the control group (*P*\<0.029, [Figure 3](#fig3){ref-type="fig"}).

In order to analyze closer the observed significant effects of the intervention on insulin, LDL cholesterol and visceral fat, we pooled the variables in the control and intervention groups into one group, adjusted them by body weight change and analyzed their differences between the quartiles of the daily step numbers. There were no significant differences between the quartiles of fasting glucose/insulin, 2-h glucose/insulin or HOMA-IR (only insulin data are shown, [Figures 4a and b](#fig4){ref-type="fig"}). However, in the highest active quartile there was a highly significant reduction in the adjusted LDL cholesterol and visceral fat area when compared with the lowest one ([Figures 4c and d](#fig4){ref-type="fig"}). The reductions when the number of daily steps exceeded 6520 were for LDL cholesterol 0.7 mmol l^−1^ (95% confidence interval 0.1--1.2 mmol l^−1^) and 16 cm^2^ (7--25 cm^2^) for visceral fat area.

Discussion
==========

This randomized controlled trial in high-risk subjects demonstrated that a 3-month structured walking exercise of light intensity (that is, walking at ∼3 km h^−1^ corresponding to ∼two MET), resulted in significant decreases in fasting and 2-h insulin levels, HOMA-IR, total and LDL cholesterol concentrations and visceral fat area. The weekly duration of our structured exercise was 120--150 min, which was closely similar to the PA guidelines recommending a minimum of 150 min per week of moderate-intensity exercise.^[@bib8],\ [@bib9]^ However, our subjects were able to perform only light intensity PA, evidently owing to their overweight/obesity status and low-maximal oxygen uptake capacity, a common problem in this high-risk subject group. Their PA level two METs present about 30% of their maximal oxygen uptake, and only 2.6% of their daily steps were above the acceleration class of ⩾1.1 g, presenting the lowest level of the three-MET activity. In two randomized studies in which objective measurements of PA were used, prediabetic subjects reached daily step numbers of 9000--10 000 and their 2-h glucose decreased at 3 and 12 months.^[@bib17],\ [@bib30]^ The median daily step counts in our subjects were 5576 (intervention group) and 4004 (control group), clearly lower than those in the two previously mentioned studies.^[@bib17],\ [@bib30]^ This is the likely reason we did not find any significant intervention effects on the fasting and 2-h glucose after 3 months. Insulin was not measured in these studies, but there was a 44% risk reduction in T2D development in the latter one.^[@bib30]^ Both studies did not record the exercise intensity and used pedometers only for compliance monitoring. Achieving 10 000 daily steps may be quite difficult for most subjects. Only seven of 68 of our subjects were able to reach 10 000 steps per day.

The effects of lifestyle modifications on insulin sensitivities have previously demonstrated a significant association with improved insulin sensitivity and body weight reduction. In the AusDiab Study, daily step counts were measured in 592 adults.^[@bib31]^ Higher step counts were associated with improved insulin sensitivity, but the effect was mediated by lower adiposity. In the Finnish Diabetes Prevention Study, a 4-year lifestyle intervention with dietary and PA counseling significantly reduced the risk of developing T2D with improvements in insulin sensitivity and weight loss.^[@bib32]^ In our study, the intervention effects on insulin were statistically significant regardless of changes in body weight and other confounding factors. The improvement in the insulin sensitivity of our subjects appeared to be mostly an independent outcome and may reflect the effects of PA on insulin signaling in the skeletal muscle.^[@bib33]^ This is in agreement with the preset finding in which the change in fitness (PA) in response to lifestyle modifications was found to have an independent effect without body weight changes on health-related outcomes in T2D patients.^[@bib34]^

The reduction in the visceral fat area we observed in our subjects between the highest and lowest active quartile was 16 cm^2^, corresponding to 10% of the total visceral fat. This is in agreement with the findings that 4 weeks of aerobic cycling exercise in obese individuals significantly reduced visceral adipose tissue volume by 12% without an effect on basal insulin or HOMA-IR.^[@bib35]^ Thus, our novel results demonstrate a clinically relevant observation, namely that even very low-PA intensity starts a chain of events reducing visceral fat mass, blood cholesterol and insulin resistance, all known to diminish the risk of developing T2D.^[@bib36]^

Henson *et al.*^[@bib37]^ recently measured sedentary time (\<25 actigraph counts per 15 s), moderate-to-vigorous intensity physical exercise activity (⩾488 counts per 15 s) and total PA (total counts) demonstrating that time spent sedentary is adversely associated with elevated 2-h glucose and triglycerides in subjects with known risk factors for T2D.^[@bib32]^ The authors concluded that sedentary behavior is a more important indicator for poor health than moderate-to-vigorous activity. Our results support these findings as an increasing number of daily steps ameliorated insulin resistance and lipid status.

The accelerometer used in the present study records the number of acceleration peaks induced by walking (steps) and their accelerations (intensities), which had not been previously used in subjects with high-T2D risk. We have used these accelerometers in previous studies to establish precise exercise threshold levels for beneficial health effects in healthy women including increased bone mass, muscle strength, maximal oxygen uptake and decrease in total and LDL cholesterol.^[@bib28],\ [@bib29]^ For the present study we also pooled accelerometer data from the intervention and control group and compared each variable between quartiles. We observed dose--response relations between LDL cholesterol and visceral fat area. Significant reductions occurred at the highest active quartiles above 6520 daily steps. Interestingly, there was no significant dose--response relation between the changes in the glucose or insulin levels between the quartiles. The difference in 2-h insulin changes between the highest and lowest active quartile was as high as 36 mU l^−1^ but did not reach statistical significance, owing to the large variation in the least active quartile.

The present study does have limitations. The intervention was short and the number of subjects relatively small. However, whole-day recordings of step-induced steps and accelerations throughout the 3-month intervention made it possible to measure accurately the amount and intensity of PA and allowed us to determine quantitatively their effects on glucose and insulin levels as well as lipid homeostasis.

Before starting the intervention, we informed all the participating subjects about their abnormal blood glucose levels and the beneficial effects of increased PA and weight reduction according to the best standard of care. In addition, the weekly downloading of the data could possibly have affected the subjects. This led to 'co-intervention\' in the control group in which high physical activities and large weight reductions were also observed in several subjects. To avoid the interference of 'co-intervention\' we analyzed associations of daily step numbers with outcome variables from all the subjects.

Our novel finding was that we were able to translate steps and accelerations to practical PA guidelines in sedentary and obese subjects with high-T2D risk. At the intensity level of 0.3--0.7 g, which is equivalent to walking 2--3 km h^−1^ or ∼two METs,^[@bib11]^ the daily number of steps needed to reduce insulin and lipid levels and visceral fat area was at least 6500, requiring ∼90 min of ambulatory activities. This goal can be achieved by walking at a speed of 2--3 km h^−1^ and/or leisure-time-, household-, commuting- and occupation-related activities.

We have previously observed in healthy adult females, who were able to exercise at acceleration levels beyond 1.1 g, that significant improvements in maximal oxygen uptake, skeletal bone masses and blood cholesterol levels were possible with daily exercises lasting for at least 15 min.^[@bib28],\ [@bib29]^ Thus, a common PA guideline is difficult to apply to subjects with different physical fitness levels, so that tailored guidelines are rather needed. Given the sedentary lifestyles that many people nowadays lead, objective measurements are necessary to establish specific PA guidelines to provide adequate protection against metabolic disorders.
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![Flow chart of the PreDiabEx study participants and dropouts from the study.](ijo2013224f1){#fig1}

![Individual distribution of mean daily steps of all the subjects (*n*=33 intervention and 35 controls) by magnitude order (control subjects, gray; intervention subjects, white). Please note the intervention effects in subjects 20--60 and two highly active subjects.](ijo2013224f2){#fig2}

![Number of daily steps (means and s.e.m.) in the five acceleration classes in intervention and control subjects. An asterisk denotes *P*\<0.05 between intervention and control groups.](ijo2013224f3){#fig3}

![Changes in fasting (**a**) and 2-h insulin (**b**), LDL cholesterol (**c**) and visceral fat area (**d**) in the physical activity quartiles: I 1780--2810, II 2940--4010, III 4010--6020 and IV 6520--21 000 daily steps. Changes in *P*-values represent significance between the lowest and highest quartiles. Step data were taken from the acceleration levels 0.3--0.7 g. Data were log-transformed and adjusted to baseline, sex, age and weight changes. Original values are used in the figures. In the violin box plot the black horizontal line is mean, orange area 95% confidential limits, narrow box II and III quartiles and green area dispersion of the observations (*n*=17 in each quartile).](ijo2013224f4){#fig4}

###### Clinical characteristics, physical activity and medication of study participants by group at baseline

  *Variable*                                    *Intervention*    *Control*    P*-value*
  -------------------------------------------- ---------------- -------------- -----------
  Number of subjects                                  33              35        
  Age (years)                                     58.1 (9.9)     59.5 (10.8)   0.565
  Women                                           24 (72.7%)      26 (74.3%)   0.885
  Weight (kg)                                    92.4 (19.4)     84.6 (14.4)   0.065
  BMI (kg m^−2^)                                  32.6 (5.7)      30.9 (4.8)   0.191
  Waist (cm)                                     98.4 (16.9)     94.4 (11.1)   0.263
  VO~2~ max (ml kg^-1^ min^−1^)                   22.5 (4.7)      23.8 (4.8)   0.284
  Systolic BP (mm Hg)                            138.5 (16.4)    150.4 (20.2)  0.026
  Diastolic BP (mm Hg)                            83.8 (8.0)      85.4 (9.5)   0.352
  *Self-reported physical activity*                                            
   Light, MET (h per week)                        1.5 (0.5)       1.4 (0.5)    0.794
   Moderate, MET (h per week)                     2.7 (1.8)       2.6 (1.8)    0.826
   Vigorous, MET (h per week)                     1.8 (2.4)       1.8 (2.7)    1
  *Self-reported education*                                                    
   Basic                                          8 (25.0%)       12 (38.7%)   0.246
   Secondary                                      17 (53.1%)      14 (45.2%)   0.531
   Tertiary                                       7 (21.9%)       5 (16.1%)    0.565
  *Self-reported medication by prescription*                                   
   Nitrates                                        1 (3.0%)       4 (11.4%)    0.188
   Antihypertensives                              18 (54.5%)      18 (51.4%)   0.798
   Diuretics                                      4 (12.1%)       4 (11.4%)    0.93
   Aspirin anti-coagulants                        6 (18.2%)       7 (20.0%)    0.85
   Lipid-lowering drugs                           12 (36.4%)      12 (34.3%)   0.859
   Bronchodilatators                               3 (9.1%)       4 (11.4%)    0.753
   Thyroxine                                       3 (9.1%)       5 (14.3%)    0.509
   Antiulcer-drugs                                4 (12.1%)       4 (11.4%)    0.93

Abbreviations: BMI, body mass index; BP, blood pressure; MET, metabolic equivalent.

Means and s.d. or percentages are given. *P*-values from *t*-tests and from *χ*^2^-test (education and medication).

###### Metabolic parameters and nutrient intakes before and after a 3-month physical activity intervention in subjects with high-T2D risk

                                         *Intervention (*N*=33)*   P              *Control (*N*=35)*   P              *Difference*[a](#t2-fn3){ref-type="fn"}   *ANOVA*[b](#t2-fn4){ref-type="fn"} (P*-value)*                                           
  -------------------------------------- ------------------------- -------------- -------------------- -------------- ----------------------------------------- ------------------------------------------------ ---------------------- ------- -------- -------
  Fasting glucose (mmol l^−1^)           6.6 (0.8)                 6.4 (0.8)      0.019                6.5 (0.7)      6.6 (1.8)                                 0.659                                            0.3 (−0.2 to 0.9)      0.256   0.2183   0.247
  2-h glucose (mmol l^−1^)               8.9 (2.6)                 7.8 (2.6)      0.017                8.7 (2.6)      7.9 (3.0)                                 0.061                                            0.2 (−0.9 to 1.3)      0.915   0.831    0.789
  Fasting insulin (mU l^−1^)             18.7 (11.0)               15.6 (10.3)    0.008                16.3 (11.9)    16.9 (15.9)                               0.757                                            3.4 (−0.8 to 7.6)      0.047   0.041    0.035
  2-h insulin (mU l^−1^)                 116.9 (70.8)              75.6 (62.7)    \<0.001              94.8 (72.8)    91.4 (60.6)                               0.794                                            26.6 ( 1.1 to 51.8)    0.003   0.003    0.003
  Homa-IR                                5.7 (3.8)                 4.6 (3.3)      0.003                4.8 (3.7)      4.9 (4.4)                                 0.939                                            1.0 (−0.2 to 2.2)      0.050   0.043    0.036
  Total cholesterol (mmol l^−1^)         5.3 (0.8)                 5.0 (0.8)      0.001                5.7 (1.3)      5.5 (1.1)                                 0.298                                            0.3 (−0.0 to 0.7)      0.064   0.062    0.041
  HDL cholesterol (mmol l^−1^)           1.4 (0.3)                 1.4 (0.4)      0.514                1.5 (0.3)      1.5 (0.3)                                 0.544                                            0.0 (−0.1 to 0.1)      0.674   0.660    0.553
  LDL cholesterol (mmol l^−1^)           3.0 (0.8)                 3.0 (0.8)      0.771                3.2 (1.2)      3.6 (1.0)                                 0.018                                            0.4 ( 0.1 to 0.7)      0.014   0.012    0.008
  Triglycerides (mmol l^−1^)             1.7 (0.6)                 1.5 (0.4)      \<0.001              1.8 (0.7)      1.7 (0.9)                                 0.391                                            0.2 (−0.0 to 0.5)      0.239   0.251    0.179
  Systolic blood pressure (mm Hg)        138.5 (16.4)              131.3 (15.2)   0.005                150.4 (20.2)   139.0 (16.0)                              \<0.001                                          1.0 (−5.4 to 7.5)      0.688   0.653    0.742
  Diastolic blood pressure (mm Hg)       83.8 (8.0)                79.1 (8.2)     0.004                85.4 (9.5)     80.1 (8.8)                                0.007                                            0.4 (−3.5 to 4.4)      0.820   0.479    0.392
  Max. O~2~ uptake (ml kg^−1^ min^−1^)   22.7 (4.6)                26.3 (6.8)     0.002                23.6 (4.8)     26.4 (5.5)                                0.002                                            −0.9 (−3.0 to 1.2)     0.394   0.450    0.428
  Weight (kg)                            92.4 (19.4)               91.5 (20.3)    0.028                84.6 (14.4)    83.3 (15.3)                               0.047                                            −0.1 (−1.6 to 1.4)     0.899   0.970     
  BMI (kg m^−2^)                         32.6 (5.7)                32.3 (6.1)     0.038                30.9 (4.8)     30.2 (4.9)                                0.011                                            −0.3 (−0.8 to 0.3)     0.379   0.402     
  Waist circumference (cm)               97.4 (17.2)               95.1 (14.1)    0.061                91.4 (9.7)     88.3 (8.4)                                0.005                                            −2.3 (−4.9 to 0.4)     0.100   0.123    0.132
  Body fat (%)                           40.0 (7.6)                37.9 (9.0)     0.018                38.6 (9.0)     37.5 (9.3)                                0.020                                            0.9 (−1.0 to 2.8)      0.279   0.284    0.199
  Visceral fat area (cm^2^)              163.7 (29.8)              155.9 (31.4)   0.013                156.3 (28.0)   154.0 (32.7)                              0.185                                            5.5 (−1.4 to 12.3)     0.073   0.082    0.030
  Skeletal mass (kg)                     29.6 (8.4)                30.4 (9.3)     0.140                28.5 (5.5)     28.6 (5.3)                                0.867                                            −0.7 (−1.9 to 0.4)     0.443   0.328    0.214
  Energy intake (kcal per day)           1766 (568)                1831 (609)     0.486                1725 (466)     1719 (550)                                0.958                                            −85 (−335 to 165)      0.683   0.735    0.764
  Protein intake (kcal per day)          77.8 (25.6)               81.5 (24.1)    0.354                73.5 (25.0)    73.4 (24.5)                               0.978                                            −5.3 (−14.7 to 4.2)    0.335   0.260    0.295
  Carbohydrate intake (kcal per day)     203.4 (73.8)              191.6 (65.9)   0.309                203.4 (66.4)   193.1 (60.7)                              0.476                                            1.5 (−28.1 to 31.0)    0.748   0.660    0.560
  Fat intake (kcal per day)              63.7 (27.2)               74.0 (33.4)    0.063                63.7 (20.7)    68.1 (27.6)                               0.339                                            −5.9 (−19.7 to 7.8)    0.407   0.521    0.497
  Gluose intake (kcal per day)           93.6 (31.4)               85.2 (37.1)    0.154                89.3 (34.0)    81.6 (34.9)                               0.377                                            −1.9 (−19.5 to 15.8)   0.878   0.923    0.953

Abbreviations: ANOVA, analysis of variance; Homa-IR, homeostasis model assessment-estimated insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Max., maximum; T2D, type 2 diabetes.

Data are mean and standard deviation (s.d.) or 95% confidence interval. *P* is paired *t*-test probability.

Model 1=controlled with baseline value. Model 2=Model 1+sex+age. Model 3=Model 2+weight change during intervention.

Based on log transformation.
